Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
Open Access
- 16 June 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (46) , 81343-81349
Abstract
Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patientsKeywords
This publication has 12 references indexed in Scilit:
- HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-upEuropean Journal of Cancer, 2016
- A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancerCancer Medicine, 2016
- Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion studyClinicoEconomics and Outcomes Research, 2015
- Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyAnnals of Oncology, 2014
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer studyAnnals of Oncology, 2014
- Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomJournal of Medical Economics, 2014
- Automated preparation of chemotherapy: Quality improvement and economic sustainabilityAmerican Journal of Health-System Pharmacy, 2014
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised studyThe Lancet Oncology, 2013
- The application of hazard analysis and critical control points and risk management in the preparation of anti-cancer drugsInternational Journal for Quality in Health Care, 2009
- Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsThe Oncologist, 2008